Hapax Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-12-2024
- Paid Up Capital ₹ 1.00 M
as on 16-12-2024
- Company Age 10 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2022)
- Profit -108.15%
(FY 2022)
- Ebitda 73.45%
(FY 2022)
- Net Worth -0.87%
(FY 2022)
- Total Assets -0.13%
(FY 2022)
About Hapax Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Sanjaykumar Jha, Prakash Patel, Kartik Raval, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232GJ2014PTC080569
- Company No.
080569
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Aug 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Hapax Pharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjaykumar Jha  | Director | 25-Aug-2014 | Current |
| Prakash Patel | Director | 02-Feb-2019 | Current |
| Kartik Raval | Director | 25-Aug-2014 | Current |
| Kalpesh Shah | Director | 02-Feb-2019 | Current |
Financial Performance of Hapax Pharma.
Hapax Pharma Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 108.15% decrease in profit. The company's net worth dipped by a decrease of 0.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hapax Pharma?
In 2022, Hapax Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Expert Second Opinion Services Private LimitedActive 3 years 2 monthsSanjaykumar Jha is a mutual person
Cuidado Medico Private LimitedActive 15 years 11 monthsSanjaykumar Jha and Kartik Raval are mutual person
Salvavita Pharmaceuticals Private LimitedActive 3 years 11 monthsSanjaykumar Jha is a mutual person
Kesar Pharma Private LimitedActive 13 years 2 monthsPrakash Patel and Kalpesh Shah are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Hapax Pharma?
Unlock and access historical data on people associated with Hapax Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hapax Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hapax Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
